Revision as of 20:25, 1 April 2015 by Ammu Susheela(talk | contribs)(Created page with "{{DrugProjectFormSinglePage |authorTag={{Ammu}} |genericName=lodoxamide tromethamine |drugClass=mast cell stabilizer |indicationType=treatment |indication=ocular disorders ref...")
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% is indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.
The dose for adults and children greater than two years of age is one to two drops in each affected eye four times daily for up to 3 months.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Lodoxamide tromethamine in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Lodoxamide tromethamine in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Lodoxamide tromethamine FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Lodoxamide tromethamine in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Lodoxamide tromethamine in pediatric patients.
Contraindications
Hypersensitivity to any component of this product.
Warnings
FOR TOPICAL OPHTHALMIC USE ONLY. NOT FOR INJECTION. As with all ophthalmic preparations containing benzalkonium chloride, patients should be instructed not to wear soft contact lenses during treatment with ALOMIDE® Ophthalmic Solution. Do not touch the dropper tip to any surface, as this may contaminate the solution.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Lodoxamide tromethamine Clinical Trials Experience in the drug label.
Postmarketing Experience
During clinical studies of ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1%, the most frequently reported ocular adverse experiences were transient burning, stinging, or discomfort upon instillation, which occurred in approximately 15% of the subjects. Other ocular events occurring in 1 to 5% of the subjects included ocular itching/pruritus, blurred vision, dry eye, tearing/discharge, hyperemia, crystalline deposits, and foreign body sensation. Events that occurred in less than 1% of the subjects included corneal erosion/ulcer, scales on lid/lash, eye pain, ocular edema/swelling, ocular warming sensation, ocular fatigue, chemosis, corneal abrasion, anterior chamber cells, keratopathy/keratitis, blepharitis, allergy, sticky sensation, and epitheliopathy.
Nonocular events reported were headache (1.5%) and (at less than 1%) heat sensation, dizziness, somnolence, nausea, stomach discomfort, sneezing, dry nose, and rash.
Drug Interactions
There is limited information regarding Lodoxamide tromethamine Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA): B
eproduction studies with lodoxamide tromethamine administered orally to rats and rabbits in doses of 100 mg/kg/day (more than 5000 times the proposed human clinical dose) produced no evidence of developmental toxicity. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% should be used during pregnancy only if clearly needed.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Lodoxamide tromethamine in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Lodoxamide tromethamine during labor and delivery.
Nursing Mothers
It is not known whether lodoxamide tromethamine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ALOMIDE® Ophthalmic Solution 0.1% is administered to nursing women.
Pediatric Use
Safety and effectiveness in pediatric patients below the age of 2 years have not been established.
Geriatic Use
No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Gender
There is no FDA guidance on the use of Lodoxamide tromethamine with respect to specific gender populations.
Race
There is no FDA guidance on the use of Lodoxamide tromethamine with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Lodoxamide tromethamine in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Lodoxamide tromethamine in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Lodoxamide tromethamine in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Lodoxamide tromethamine in patients who are immunocompromised.
There is limited information regarding Lodoxamide tromethamine Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Lodoxamide tromethamine and IV administrations.
Overdosage
There have been no reports of ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% overdose following topical ocular application. Accidental overdose of an oral preparation of 120 to 180 mg of lodoxamide resulted in a temporary sensation of warmth, profuse sweating, diarrhea, light-headedness, and a feeling of stomach distension; no permanent adverse effects were observed. Side effects reported following systemic oral administration of 0.1 mg to 10.0 mg of lodoxamide include a feeling of warmth or flushing, headache, dizziness, fatigue, sweating, nausea, loose stools, and urinary frequency/urgency. The physician may consider emesis in the event of accidental ingestion.
Pharmacology
There is limited information regarding Lodoxamide tromethamine Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Lodoxamide tromethamine Mechanism of Action in the drug label.
Structure
ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% is a sterile ophthalmic solution containing the mast cell stabilizer lodoxamide tromethamine for topical administration to the eyes. Lodoxamide tromethamine is a white, crystalline, water-soluble powder with a molecular weight of 553.91. The chemical structure is presented below:
